A Prospective Observational Study On Monitoring And Reporting Of Adverse Drug Reactions Among Oncology Patients In A Tertiary Care Hospital
|
|
Author:
|
S.DIVYA , T.BHAVITHA, T.CHAITANYA SAI VENKAT, V.CHANDRU, K.UMAMAHESWARA RAO, M.POOJITHA
|
Abstract:
|
Background: Adverse drug reaction (ADR) is defined as “a response to a drug, which is noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease, for the modifications of physiological function.” A clinical pharmacist plays important role in early detection of ADRs, which help in minimizing the damage by treating and preventing the ADRs. Pharmacovigilance studies are essential in oncology and its main aim is to reduce the risk of drug related problems in patients.
Methods: A prospective observational study was conducted to assess the ADRs of chemotherapeutic agents in oncology patients. It was conducted in the department of pharmacovigilance, SVIMS-SPMC(W). A predesigned data collection form was used to collect information about the type of adverse drug reaction caused during the treatment of chemotherapy to oncology patients. The ADRs are assessed using ADR form.
Results: Among 80 patients, 45 are females and 35 are males. The data was analyzed for age distribution and the mean age was 49+13.2 years. Out of 80 patients, who were using cisplatin, 25% developed adverse effects. hematological (anemia, leukopenia, thrombocytopenia, neutropenia, leukocytosis, and myelosuppression’s) (65%) was the most found adverse effect.
Conclusion: ADRs are increasing day by day with cancer chemotherapy treatment. Identifying the ADR helpful in prevention of life-threatening causes in initial stage. Pharmacovigilance is an important tool which might determine the ADRs of cancer therapy by regular monitoring the clinical and laboratory findings.
|
Keyword:
|
Adverse drug reactions, Cancer chemotherapy, pharmacovigilance
|
EOI:
|
-
|
DOI:
|
https://doi.org/10.31838/ijpr/2023.15.01.010
|
Download:
|
Request For Article
|
|
|